Skip to main content Skip to main navigation menu Skip to site footer

Mortality of COVID-19 patients with comorbidity of diabetes mellitus: a retrospective study

  • Difran Nobel Bistara ,
  • Susanti ,
  • Arif Helmi Setiawan ,
  • Umi Hanik ,
  • Thomas Ari Wibowo ,
  • Niken Setyaningrum ,
  • Satriya Pranata ,


Background: Chronic diseases such as diabetes mellitus (DM) are risk factors that cause COVID-19 patients to experience high morbidity and mortality rates. Diabetes becomes the most hazardous comorbid during the pandemic because it increases the likelihood of more serious effects when infected with the coronavirus. This study aims to provide an overview of mortality in patients with COVID-19 who have comorbid DM.

Methods: The research design used was a case-control study design with a retrospective approach. The population in this study were all COVID-19 patients with comorbid DM. The study criteria were COVID-19 patients with comorbid diabetes mellitus. Multivariate analysis using logistic regression analysis was performed to determine the parametric analysis of correlation tests.

Results: The results of a multivariate analysis of variables related to mortality rates in COVID-19 patients with comorbid diabetes mellitus, one of which is other comorbidities. Concomitant acute respiratory distress syndrome became the only variable with a p-value <0.05.

Conclusion: Acute respiratory distress syndrome is another comorbid disease that is the number one cause of COVID-19 patients dying during the treatment period, apart from the pure diabetes mellitus that they suffer.


  1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–11. Available from:
  2. Bistara DN, Wardani EM, Susanti, Santoso APR, Fasya AHZ, Andini A. The effect of discharge planning on the stability of blood sugar levels in type 2 diabetes mellitus patients. Bali Med J. 2022;11(3):1180–4. Available from:
  3. Sharivker A. Diabetes Mellitus during the Coronavirus Disease 2019 Pandemic. 2022.
  4. Kementrian Kesehatan Republik Indonesia. Situasi dan Analisis Diabetes. In: Infodatin. Jakarta; 2016. p. 1–8. Available from:
  5. Kementerian Kesehatan RI. Laporan Riskesdas 2018. Lap Nas Riskesdas 2018. 2018;53(9):154–65. Available from: No. 57 Tahun 2013 tentang PTRM.pdf
  6. Bistara DN, Ainiyah N, Umamah F, Septianingrum Y, Fitriasari A, Wijayanti L, et al. Clinical characteristics of confirmed patients with COVID-19: A perspective from tropical region. Bali Med J. 2022;11(2):1004–8. Available from:
  7. Mallah SI, Ghorab OK, Al-Salmi S, Abdellatif OS, Tharmaratnam T, Iskandar MA, et al. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35. Available from:
  8. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging Dis. 2020;11(3):668–78. Available from:
  9. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health. 2020;45(6):1270–82. Available from:
  10. Pérez-Belmonte LM, Torres-Peña JD, López-Carmona MD, Ayala-Gutiérrez MM, Fuentes-Jiménez F, Huerta LJ, et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med. 2020;18(1):359. Available from:
  11. Sironi M, Hasnain SE, Rosenthal B, Phan T, Luciani F, Shaw M-A, et al. SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. Infect Genet Evol. 2020/05/29. 2020;84:104384. Available from:
  12. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. lancet HIV. 2020/12/11. 2021;8(1):e24–32. Available from:
  13. Araya F. Modeling the spread of COVID-19 on construction workers: An agent-based approach. Saf Sci. 2020/09/29. 2021;133:105022. Available from:
  14. Aksoy CG, Ganslmeier M, Poutvaara P. Public attention and policy responses to COVID-19 pandemic⋆ [Internet]. Cold Spring Harbor Laboratory; 2020. Available from:
  15. Triyono EA, Wahyuhadi J, Prajitno JH, Novida H, Siagian N, Cahyani C, et al. Clinical characteristics and outcomes of hospitalized COVID-19 patients with diabetes mellitus in East Java, Indonesia: A cross-sectional study. F1000Research. 2022;11:684. Available from:
  16. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis. SSRN. 2020;3566166. Available from:
  17. Li G, Chen Z, Lv Z, Li H, Chang D, Lu J. Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. Int J Endocrinol. 2021;2021:7394378. Available from:
  18. Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Front Endocrinol (Lausanne). 2021;11:600439. Available from:
  19. Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020/07/01. 2020;86:106749. Available from:
  20. Chau AS, Weber AG, Maria NI, Narain S, Liu A, Hajizadeh N, et al. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. Arthritis & Rheumatol. 2020;73(1):23–35. Available from:
  21. Ahmed YM, Abdelgawad MA, Shalaby K, Ghoneim MM, AboulMagd AM, Abdelwahab NS, et al. Pioglitazone Synthetic Analogue Ameliorates Streptozotocin-Induced Diabetes Mellitus through Modulation of ACE 2/Angiotensin 1-7 via PI3K/AKT/mTOR Signaling Pathway. Pharmaceuticals (Basel). 2022;15(3):341. Available from:
  22. Obukhov AG, Stevens BR, Prasad R, Li Calzi S, Boulton ME, Raizada MK, et al. SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. Diabetes. 2020/07/15. 2020;69(9):1875–86. Available from:
  23. Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020/02/14. 2020;209:107503. Available from:
  24. Shofler D, Rai V, Mansager S, Cramer K, Agrawal DK. Impact of resolvin mediators in the immunopathology of diabetes and wound healing. Expert Rev Clin Immunol. 2021;17(6):681–90. Available from:
  25. Marhl M, Grubelnik V, Magdič M, Markovič R. Diabetes and metabolic syndrome as risk factors for COVID-19. Diabetes Metab Syndr. 2020/05/08. 2020;14(4):671–7. Available from:

How to Cite

Bistara, D. N., Susanti, Setiawan, A. H., Hanik, U., Wibowo, T. A. ., Niken Setyaningrum, & Satriya Pranata. (2023). Mortality of COVID-19 patients with comorbidity of diabetes mellitus: a retrospective study. Bali Medical Journal, 12(3), 2912–2916.




Search Panel